Breanne Maloney
Overview
Explore the profile of Breanne Maloney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maloney B, Park S, Sowizral M, Brackett I, Moslehi R, Chung W, et al.
Clin Biochem
. 2023 Jul;
118:110614.
PMID: 37479106
Introduction: Newborn screening for Duchenne muscular dystrophy can be performed via a first-tier creatine kinase-MM measurement followed by reflex testing to second-tier molecular analysis of the DMD gene. In order...
2.
Tavakoli N, Gruber D, Armstrong N, Chung W, Maloney B, Park S, et al.
Ann Clin Transl Neurol
. 2023 Jun;
10(8):1383-1396.
PMID: 37350320
Objective: Duchenne muscular dystrophy (DMD) is an X-linked disorder resulting in progressive muscle weakness and atrophy, cardiomyopathy, and in late stages, cardiorespiratory impairment, and death. As treatments for DMD have...
3.
Wynn J, Tavakoli N, Armstrong N, Gomez J, Koval C, Lai C, et al.
Int J Neonatal Screen
. 2022 Apr;
8(2).
PMID: 35466194
Seven months after the launch of a pilot study to screen newborns for Duchenne Muscular Dystrophy (DMD) in New York State, New York City became an epicenter of the coronavirus...
4.
Park S, Maloney B, Caggana M, Tavakoli N
Muscle Nerve
. 2022 Mar;
65(6):652-658.
PMID: 35307847
Introduction/aims: Creatine kinase-MM (CK-MM) is a marker of skeletal muscle damage. Detection of elevated levels of CK-MM in newborns can enable an early suspicion of the diagnosis of Duchenne muscular...
5.
Pearce M, DeMartino L, McMahon R, Hamel R, Maloney B, Stansfield D, et al.
Mol Genet Metab Rep
. 2016 Jun;
7:1-7.
PMID: 27331001
From 2007 to 2014 the New York State (NYS) Newborn Screening (NBS) program screened 2 million newborns for congenital adrenal hyperplasia (CAH). The data was analyzed to determine factors that...
6.
Hughes E, Stevens C, Saavedra-Matiz C, Tavakoli N, Krein L, Parker A, et al.
Hum Mutat
. 2015 Nov;
37(2):201-8.
PMID: 26538069
Infants are screened for cystic fibrosis (CF) in New York State (NYS) using an IRT-DNA algorithm. The purpose of this study was to validate and assess clinical validity of the...
7.
Kay D, Maloney B, Hamel R, Pearce M, DeMartino L, McMahon R, et al.
Eur J Pediatr
. 2015 Aug;
175(2):181-93.
PMID: 26293390
Conclusion: Considerations for CF screening algorithms should include IRT variations resulting from age at specimen collection, sex, race/ethnicity, season, and manufacturer kit lots. What Is Known: Measuring IRT level in...
8.
Kay D, Langfelder-Schwind E, DeCelie-Germana J, Sharp J, Maloney B, Tavakoli N, et al.
Pediatr Pulmonol
. 2015 Jun;
50(8):771-80.
PMID: 26098992
Newborn screening for Cystic Fibrosis (CF) began in New York in October, 2002 using immunoreactive trypsinogen (IRT)/DNA methodology. Infants with at least one CFTR mutation or very high IRT and...